Boehringer adds survodutide bioequivalence trial alongside BI 3000202 transporter study

Boehringer Ingelheim has two registry updates this week, both early-stage pharmacokinetic studies.

• NCT07768813 is a Phase 1, open-label, two-period crossover trial comparing a pre-filled syringe formulation and a vial formulation of survodutide (BI 456906) in healthy participants and those with overweight or obesity. The trial aims to establish the bioequivalence of survodutide in a pre-filled syringe (reference product) and in a vial (test product) in male and female trial participants who are healthy or otherwise healthy with overweight/obesity, following subcutaneous administration.¹ The study is listed as active not recruiting, with enrollment of 44 participants (actual)¹ at a site in Mannheim, Germany.
• NCT07774325 is a Phase 1, open-label, three-period crossover trial in healthy male volunteers testing how ciclosporin and itraconazole affect blood levels of BI 3000202. The study is designed to investigate the effects of multiple doses of Itraconazole and multiple doses of Ciclosporin on the pharmacokinetics of BI 3000202 in plasma following a single oral dose in healthy male trial participants.² The trial is listed as active not recruiting, with enrollment estimated at 16 participants² at a site in Biberach, Germany.